1. Home
  2. NUVL vs CPT Comparison

NUVL vs CPT Comparison

Compare NUVL & CPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$123.86

Market Cap

9.8B

Sector

Health Care

ML Signal

HOLD

Logo Camden Property Trust

CPT

Camden Property Trust

HOLD

Current Price

$113.16

Market Cap

10.8B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
CPT
Founded
2017
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
9.8B
10.8B
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
NUVL
CPT
Price
$123.86
$113.16
Analyst Decision
Strong Buy
Buy
Analyst Count
16
17
Target Price
$134.75
$115.28
AVG Volume (30 Days)
2.4M
976.7K
Earning Date
05-08-2026
04-30-2026
Dividend Yield
N/A
4.03%
EPS Growth
N/A
136.00
EPS
N/A
0.40
Revenue
N/A
$12,967,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1,239.49
$2.60
P/E Ratio
N/A
$283.25
Revenue Growth
N/A
81.69
52 Week Low
$71.14
$96.53
52 Week High
$123.86
$119.81

Technical Indicators

Market Signals
Indicator
NUVL
CPT
Relative Strength Index (RSI) 67.02 50.93
Support Level $98.56 $105.41
Resistance Level N/A $116.59
Average True Range (ATR) 0.15 1.94
MACD -0.67 -0.35
Stochastic Oscillator 93.27 42.88

Price Performance

Historical Comparison
NUVL
CPT

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About CPT Camden Property Trust

Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 175 multifamily properties comprised of nearly 59,921 apartment homes across the United States.

Share on Social Networks: